Treatment Clinical Trials for Endometrial Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for endometrial cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 86

  • HIIT before Surgery in Improving Outcomes in Patients with Endometrial Cancer

    This trial studies how well HIIT before surgery works in improving outcomes in patients with endometrial cancer. HIIT is an exercise strategy where short intense exercise periods are interspersed with recovery periods. Endometrial cancer is an obesity driven disease. Obesity creates a tumor enhancing environment. HIIT before surgery may improve outcomes in patients with endometrial cancer by slowing development of the tumor.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Talazoparib and Radiation Therapy in Treating Patients with Locally Recurrent Gynecologic Cancers

    This phase I trial studies the side effects and best dose of talazoparib in combination with radiation therapy and to see how well they work in treating patients with gynecologic cancers that have come back after previous treatment (recurrent). Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving talazoparib in combination with radiation therapy may work better in treating patients with gynecologic cancers.
    Location: M D Anderson Cancer Center, Houston, Texas

  • TSR-042 and Radiation for the Treatment of Stage I-II Endometrial Cancer

    This phase I trial studies the side effects of TSR-042 and radiation in treating stage I-II endometrial cancer. Immunotherapy with TSR-042, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving TSR-042 in combination with radiation therapy may work better in treating patients with endometrial cancer compared to radiation therapy alone.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer

    The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3434172, a PD-1 / PD-L1 bispecific antibody, in participants with advanced solid tumors.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Aerobic Training in Supporting Patients with Breast, Endometrial, or Prostate Cancer before Surgery

    This early phase I trial studies the safest level of aerobic training and to see how well it works in supporting patients with breast, endometrial, or prostate cancer who are undergoing surgery. Aerobic exercise may improve the outcomes of their cancers.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Standard Dose Fractionation Regimens for Vaginal Brachytherapy in Treating Sexual Dysfunction in Patients with Stage I-II Endometrial Cancer After Surgery

    This phase III trial studies how well standard high or low dose fractionation regimen for vaginal brachytherapy works in treating sexual dysfunction in patients with stage I-II endometrial cancer after surgery. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Undergoing a low dose fractionation regimen may work better than a high dose fractionation regimen in treating sexual dysfunction in patients with stage I-II endometrial cancer.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia

  • Pembrolizumab and Chemotherapy in Treating Patients with High-Grade Obesity-Driven Endometrial Cancer

    This early phase I trial studies how well pembrolizumab works before surgery and in combination with standard chemotherapy after surgery in treating patients with high-grade obesity-driven endometrial cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab before surgery and in combination with standard chemotherapy after surgery may work better in patients with endometrial cancer.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Megestrol Acetate with or without Pterostilbene in Treating Patients with Endometrial Cancer Undergoing Hysterectomy

    This phase II trial studies how well megestrol acetate with or without pterostilbene works in treating patients with endometrial cancer undergoing hysterectomy. Drugs used in chemotherapy, such as megestrol acetate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pterostilbene is an antioxidant found in blueberries or grapes, and it has been shown to be effective in killing tumor cells and reducing cancer burden. It is not yet known whether giving megestrol acetate with or without pterostilbene may work better in treating patients with endometrial cancer.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

    This is a Phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD and clinical activity of AB928 in combination with AB122 in participants with advanced malignancies.
    Location: 2 locations

  • Niraparib and Copanlisib in Treating Patients with Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    This phase Ib trial studies the best dose and side effects of niraparib and copanlisib in treating patients with endometrial, ovarian, primary peritoneal, or fallopian tube cancer that has come back. Niraparib and copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and rucaparib camsylate in treating participants with endometrial, ovarian, fallopian tube or primary peritoneal cancer that has come back. Drugs such as mirvetuximab soravtansine are antibodies linked to a toxic substance and may help find certain tumor cells and kill them without harming normal cells. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving mirvetuximab soravtansine and rucaparib camsylate may work better in treating participants with recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

    The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
    Location: Hackensack University Medical Center, Hackensack, New Jersey

  • Atezolizumab and Bevacizumab in Treating Patients with Advanced, Recurrent, or Refractory Endometrial Cancer

    This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with endometrial cancer that has spread to other places in the body, has come back, or does not respond to treatment. Immunotherapy with atezolizumab and bevacizumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread.
    Location: Stephenson Cancer Center, Oklahoma City, Oklahoma

  • Nivolumab with or without Ipilimumab in Treating Patients with Recurrent or High Grade Gynecologic Cancer with Metastatic Peritoneal Carcinomatosis

    This phase Ib trial studies the side effects and best dose of nivolumab with or without ipilimumab in treating patients with female reproductive cancer that has come back (recurrent) or is high grade and has spread extensively throughout the peritoneal cavity (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Bevacizumab and Rucaparib in Treating Patients with Recurrent Cervical or Endometrial Carcinoma

    This phase II trial studies how well bevacizumab and rucaparib work in treating patients with cervical or endometrial cancer that has come back. Immunotherapy with monoclonal antibodies, such as bevacizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bevacizumab and rucaparib may be helpful in shrinking the tumors, keeping them from growing or spreading, or helping patients live longer.
    Location: Stephenson Cancer Center, Oklahoma City, Oklahoma

  • Stereotactic Body Radiation Therapy in Treating Patients with Recurrent Primary Ovarian or Uterine Cancer

    This phase I trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with ovarian or uterine cancer that has come back. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.
    Location: University of Colorado Hospital, Aurora, Colorado

  • Vaginal Cuff Brachytherapy Followed by Carboplatin and Paclitaxel in Treating Patients with Stage II Endometrial Cancer after Surgery

    This phase II trial studies how well vaginal cuff brachytherapy (radiation to the upper part of the vagina) followed by carboplatin and paclitaxel works in treating patients with stage II endometrial cancer after surgery. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carboplatin and paclitaxel following vaginal cuff brachytherapy may work better than the standard treatment of radiation to the vagina or entire pelvis.
    Location: Stephenson Cancer Center, Oklahoma City, Oklahoma

  • Selumetinib and Olaparib in Treating Participants with Relapsed or Refractory and Advanced Endometrial, Ovarian, or Other Solid Tumors with RAS Pathway Alterations

    This phase I / Ib trial studies the side effects and best dose of selumetinib and olaparib in treating participants with endometrial, ovarian, or other solid tumors with RAS pathway alterations that have come back (relapsed) or do not respond to treatment (refractory) and have spread to other places in the body (advanced). Selumetinib and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • PI3K-beta Inhibitor GSK2636771 and Pembrolizumab in Treating Patients with Stage III-IV Cancer and PTEN Loss

    This phase I / II trial studies the side effects and best dose of PI3K-beta inhibitor GSK2636771 when given together with pembrolizumab and to see how well they work in treating patients with stage III-IV cancer and PTEN loss. PI3K-beta inhibitor GSK2636771 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving PI3K-beta inhibitor GSK2636771 and pembrolizumab may work better in treating patients with metastatic cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • VSV-hIFNbeta-NIS with or without Ruxolitinib Phosphate in Treating Patients with Stage IV or Recurrent Endometrial Cancer

    This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib phosphate in treating patients with stage IV endometrial cancer or endometrial cancer that has come back. The study virus, VSV-hIFNbeta-NIS, has been changed so that it has restricted ability to spread to tumor cells and not to healthy cells. It also contains a gene for a protein, NIS, which helps the body concentrate iodine making it possible to track where the virus goes. VSV-hIFNbeta-NIS may be able to kill tumor cells without damaging normal cells. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving VSV-hIFNbeta-NIS with ruxolitinib phosphate may work better in treating patients with endometrial cancer compared to VSV-hIFNbeta-NIS alone.
    Location: Mayo Clinic, Rochester, Minnesota

  • A Study Evaluating MM-310 in Patients With Solid Tumors

    MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid tumors. In the first part of the study, MM-310 will be assessed as a monotherapy until a maximum tolerated dose (MTD) is established. After an MTD of MM-310 as a monotherapy is established, an expansion cohort and MM-310 in combination with other therapies will be assessed.
    Location: Duke University Medical Center, Durham, North Carolina

  • Pembrolizumab in Treating Patients with Recurrent or Metastatic Hypermutated / Ultramutated Endometrial Cancer

    This phase II trial studies how well pembrolizumab works in treating patients with endometrial cancer that has a high number of genetic mutations (hypermutated / ultramutated) and has come back (recurrent) or that has spread to other parts of the body (metastatic). Immunotherapy with antibodies, such as pembrolizumab, may remove the brake on the body's immune system and may interfere with the ability of tumor cells to grow and spread.
    Location: Yale University, New Haven, Connecticut

  • Metformin Hydrochloride and Doxycycline in Treating Patients with Localized Breast, Uterine, or Cervical Cancer

    This phase II trial studies how well metformin hydrochloride works together with doxycycline in treating patients with localized breast, uterine, or cervical cancer. Metformin hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Doxycycline may stop the growth of bacteria by keeping them from making proteins and minimized the toxic side effects of anti-cancer therapy. It is not yet known whether giving metformin hydrochloride together with doxycycline may be a better way in treating patients with localized breast, uterine, or cervical cancer.
    Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

  • The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

    The Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Participants With Advanced Solid Tumors
    Location: 4 locations

  • Selective Surgical Staging in Predicting Lymph Node Removal in Patients with Endometrial Cancer Undergoing Surgery

    This clinical trial evaluates selective surgical staging in the treatment of women with early stage endometrial cancer (EC). The standard treatment for women with EC includes the surgical removal of the uterus (hysterectomy), both fallopian tubes and ovaries (bilateral salpingo-oophorectomy), and sometimes the lymph nodes (lymph node sampling). Even though this is a common malignancy, gynecologic oncologists still disagree on the best treatment for early EC. Some surgeons choose not to remove any lymph nodes, some perform lymph node sampling, and others remove all related lymph nodes (lymphadenectomy). Since lymph node removal is associated with adverse events, it should only be performed when necessary. By performing a systematic examination of the uterus after its removal (intraoperative consultation, IOC), doctors can better determine whether or not lymphadenectomy should be performed. Using this treatment strategy, the extent of the surgery is tailored to match the risk that the woman’s lymph nodes will be involved by cancer. After completion of the IOC, women with high-risk cancers are treated with lymphadenectomy while women with low-risk cancers are not.
    Location: University of Kentucky / Markey Cancer Center, Lexington, Kentucky